Cargando…

Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is an uncommon variant of non-Hodgkin lymphoma (NHL) with high aggressiveness and poor prognosis. Although complete remission (CR) could be achieved with therapy, some patients remain refractory or recurrently with a worse response to salva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yu, Li, Qing, Ma, Jingjing, Kang, Hui, Lin, Zhiguang, Wang, Yang, Ma, Yan, Chen, Bobin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174451/ https://www.ncbi.nlm.nih.gov/pubmed/37182159 http://dx.doi.org/10.3389/fonc.2023.1098785

Ejemplares similares

Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study
por: Ma, Jingjing, et al.
Publicado: (2022)

P1143: ZANUBRUTINIB PLUS CYTARABINE IN PATIENTS WITH REFRACTORY/RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Lin, Zhiguang, et al.
Publicado: (2023)

Improvement of outcomes of an escalated high‐dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study
por: Li, Qing, et al.
Publicado: (2021)

Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma
por: Lin, Zhiguang, et al.
Publicado: (2023)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Liu, Weiping, et al.
Publicado: (2021)

Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series
por: Yang, Chuanwei, et al.
Publicado: (2022)

Relapsed Primary Central Nervous System Lymphoma: Current Advances
por: Tao, Kaiyan, et al.
Publicado: (2021)

High Level of IL-10 in Cerebrospinal Fluid is Specific for Diagnosis of Primary Central Nervous System Lymphoma
por: Shao, Jie, et al.
Publicado: (2020)

Real-World Impact of Surgical Excision on Overall Survival in Primary Central Nervous System Lymphoma
por: Deng, Xiangyang, et al.
Publicado: (2020)

Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma
por: Jeong, Sun Young, et al.
Publicado: (2023)

Central Nervous System Involvement in Patients with Diffuse Large B Cell Lymphoma: Analysis of the Risk Factors and Prognosis from a Single-Center Retrospective Cohort Study
por: Ma, Jingjing, et al.
Publicado: (2019)

ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases
por: Ungur, Rodica, et al.
Publicado: (2015)

Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center
por: Kopińska, A., et al.
Publicado: (2021)

Case report: Relapsed/refractory extranodal natural killer/T-cell lymphoma nasal type with extensive central nervous system involvement
por: Dapkevičiūtė-Purlienė, Austėja, et al.
Publicado: (2023)

Treatment selection for patients with relapsed or refractory follicular lymphoma
por: Skarbnik, Alan Z., et al.
Publicado: (2023)

Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report
por: Liu, Wanying, et al.
Publicado: (2022)

Stereotactic Radiotherapy for Recurrent Post-Transplant Primary Central Nervous System Lymphoma
por: Benitez, Cecil M, et al.
Publicado: (2021)

Local Control of Primary Dural Central Nervous System Lymphoma Achieved With Radiotherapy
por: Vallejo, Alexandra, et al.
Publicado: (2021)

Therapeutic Effect of CAOLD Chemotherapy Regimen on Patients With Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: A Case Study
por: Liu, Yu, et al.
Publicado: (2022)

A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis
por: Wu, Zhentian, et al.
Publicado: (2023)

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
por: Tu, Sanfang, et al.
Publicado: (2019)

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
por: Nepal, Gaurav, et al.
Publicado: (2022)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022)

Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review
por: Radhakrishnan, Vivek S., et al.
Publicado: (2022)

An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy
por: Farooq, Faheem, et al.
Publicado: (2023)

All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma
por: Fante, Matthias A., et al.
Publicado: (2022)

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
por: Fan, Ni, et al.
Publicado: (2017)

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

Socioeconomic deprivation and survival outcomes in primary central nervous system lymphomas
por: Deng, Xiangyang, et al.
Publicado: (2022)

Predicting cancer relapse following lung stereotactic radiotherapy: an external validation study using real-world evidence
por: Davey, Angela, et al.
Publicado: (2023)

Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study
por: Guan, Tianwang, et al.
Publicado: (2021)

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
por: Hux, Margaret, et al.
Publicado: (2016)

Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
por: Okita, Yoshiko, et al.
Publicado: (2021)

Pretreatment diffusion-weighted imaging for prediction of relapsed and refractory primary central nervous system lymphoma
por: Chien, Hsi-Cheng, et al.
Publicado: (2023)

Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
por: Ladbury, Colton, et al.
Publicado: (2022)

Primary Central Nervous System Lymphoma With Systemic Recurrence
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors
por: Guo, Xiaopeng, et al.
Publicado: (2023)

Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience
por: Iwabuchi, Michio, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k66mcgd35jc935egtahjvri9ss